Melanocytic Lesions: Difference between revisions
No edit summary |
No edit summary |
||
| Line 571: | Line 571: | ||
'''Table 6. Comparison of rates of abnormalities reported in Spitzoid lesions in three or more manuscripts.''' | '''Table 6. Comparison of rates of abnormalities reported in Spitzoid lesions in three or more manuscripts.'''* Table derived from Barron et al., 2026 [<nowiki>PMID 41898865</nowiki><ref name=":0" />; open access]. | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Region''' | |'''Region''' | ||
| Line 578: | Line 578: | ||
|'''Spitz Nevus (%)''' | |'''Spitz Nevus (%)''' | ||
|'''Spitz Melanocytoma (%)''' | |'''Spitz Melanocytoma (%)''' | ||
|'''Spitzoid Melanoma (%)''' | |'''Spitzoid/Spitz Melanoma (%)''' | ||
|'''Manuscripts''' | |'''Number of Manuscripts''' | ||
|- | |- | ||
|6p25 | |6p25 | ||
| Line 639: | Line 639: | ||
|FISH | |FISH | ||
|at least 1 CNA | |at least 1 CNA | ||
| | |several | ||
|14 | |14 | ||
|18 | |18 | ||
| Line 647: | Line 647: | ||
|CMA | |CMA | ||
|>3 CNAs | |>3 CNAs | ||
| | |many | ||
|2 | |2 | ||
|16 | |16 | ||
| Line 654: | Line 654: | ||
|} | |} | ||
<nowiki>*</nowiki>The symbol “-” designates data not available | |||
'''Table 7. CNAs reported in at least 3 manuscripts in at least 50 cases of primary melanomas and 50 cases of metastases with significant difference in rates (P-values given for differences).''' Individual P-values indicate whether each abnormality is significantly greater than 5%. Rates in bold were the greater of the comparison between primary and metastatic melanomas. Table derived from Barron et al., 2026 [<nowiki>PMID 41898865</nowiki><ref name=":0" />; open access]. | |||
'''Table 7. CNAs reported in at least 3 manuscripts in at least 50 cases of primary melanomas and 50 cases of metastases with significant difference in rates (P-values given for differences).*''' Individual P-values indicate whether each abnormality is significantly greater than 5%. Rates in bold were the greater of the comparison between primary and metastatic melanomas. Table derived from Barron et al., 2026 [<nowiki>PMID 41898865</nowiki><ref name=":0" />; open access]. | |||
{| class="wikitable" | {| class="wikitable" | ||
|'''Region''' | |'''Region''' | ||
|'''Abnormality''' | |'''Abnormality''' | ||
|'''Genes''' | |'''Genes Affected''' | ||
|'''Rate Primary (%)''' | |'''Rate in Primary (%)''' | ||
|'''P-value (P)''' | |'''P-value Primary (P)''' | ||
|'''Rate Metastasis (%)''' | |'''Rate in Metastasis (%)''' | ||
|'''P-value | |'''P-value Metastasis''' | ||
|'''P- | |'''P-value Difference''' | ||
|''' | |'''Number of Primary Melanoma Cases''' | ||
|''' | |'''Number of Metastasis Cases''' | ||
|- | |- | ||
|3p13 | |3p13 | ||
| Line 725: | Line 727: | ||
|7q31 | |7q31 | ||
|gain | |gain | ||
|''MET, CAV1'' | |''MET, CAV1'', others | ||
|32 | |32 | ||
|<0.001 | |<0.001 | ||
| Line 800: | Line 802: | ||
|69 | |69 | ||
|} | |} | ||
<nowiki>*</nowiki>The symbol “-” designates data not available | |||